Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes
| Autor: | John Mascarenhas, Michael R. Savona, Nicole Carreau, Douglas Tremblay, Marina Kremyanskaya |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Blood transfusion Iron Overload Anemia medicine.medical_treatment Disease Iron Chelating Agents 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine parasitic diseases medicine In patient Blood Transfusion Myelofibrosis business.industry Myelodysplastic syndromes Hematology Iron chelation therapy medicine.disease Prognosis Treatment Outcome Primary Myelofibrosis 030220 oncology & carcinogenesis Myelodysplastic Syndromes Immunology Transfusion dependence business 030215 immunology |
| Zdroj: | Blood reviews. 30(5) |
| ISSN: | 1532-1681 |
| Popis: | Myelofibrosis (MF) and myelodysplastic syndrome (MDS) are hematopoietic stem cell disorders associated with cytopenias and red blood cell (RBC) transfusion dependence. Iron overload (IO) as a consequence of RBC transfusion dependence and its effect on outcomes in MF has not been formally studied. However, IO is a demonstrated poor prognostic feature in patients with MDS and congenital or acquired chronic anemias. Evidence that iron chelation therapy (ICT) reduces the deleterious effects of IO in MDS has led to speculation of benefit in MF. However, data supporting the use of ICT in MF is lacking. Neither disease has clear consensus guidelines for the use of ICT. Moreover, JAK-STAT inhibition, the cornerstone of MF treatment, often contributes to anemia and transfusional requirements. This manuscript reviews known and potential implications of IO in MF and highlights the need for prospective clinical investigations of ICT with consideration in the setting of JAK2 inhibitor therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect